Phathom Pharmaceuticals (PHAT) Competitors $5.67 +0.13 (+2.35%) Closing price 04:00 PM EasternExtended Trading$5.68 +0.01 (+0.19%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PHAT vs. ARQT, AMPH, IMCR, AAPG, KNSA, DYN, GPCR, ARDX, INDV, and NRIXShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), Immunocore (IMCR), Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Ardelyx (ARDX), Indivior (INDV), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Arcutis Biotherapeutics Amphastar Pharmaceuticals Immunocore Ascentage Pharma Group International Kiniksa Pharmaceuticals Dyne Therapeutics Structure Therapeutics Ardelyx Indivior Nurix Therapeutics Arcutis Biotherapeutics (NASDAQ:ARQT) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation. Does the media refer more to ARQT or PHAT? In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 3 mentions for Arcutis Biotherapeutics and 2 mentions for Phathom Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.25 beat Phathom Pharmaceuticals' score of 0.05 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ARQT or PHAT? Phathom Pharmaceuticals received 27 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 72.58% of users gave Phathom Pharmaceuticals an outperform vote while only 65.63% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformArcutis BiotherapeuticsOutperform Votes6365.63% Underperform Votes3334.38% Phathom PharmaceuticalsOutperform Votes9072.58% Underperform Votes3427.42% Do analysts rate ARQT or PHAT? Arcutis Biotherapeutics presently has a consensus price target of $16.60, indicating a potential upside of 27.50%. Phathom Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 305.64%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals and insiders believe in ARQT or PHAT? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ARQT or PHAT? Arcutis Biotherapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Is ARQT or PHAT more profitable? Arcutis Biotherapeutics has a net margin of -140.97% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-140.97% -119.11% -45.95% Phathom Pharmaceuticals -1,292.14%N/A -79.57% Which has preferable earnings & valuation, ARQT or PHAT? Phathom Pharmaceuticals has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$138.71M10.99-$262.14M-$1.79-7.27Phathom Pharmaceuticals$680K570.17-$201.59M-$5.69-1.00 SummaryArcutis Biotherapeutics and Phathom Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$387.72M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-1.006.1326.4618.82Price / Sales570.17312.72448.1776.45Price / CashN/A67.8344.0437.47Price / Book-4.466.747.634.64Net Income-$201.59M$138.11M$3.18B$245.69M7 Day Performance-1.73%-2.02%-1.82%-2.63%1 Month Performance-16.49%-1.54%0.22%-2.37%1 Year Performance-44.47%-3.14%17.49%13.65% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.5178 of 5 stars$5.67+2.3%$23.00+305.6%-45.5%$387.72M$680,000.00-1.00110Gap UpARQTArcutis Biotherapeutics2.2974 of 5 stars$12.78+3.8%$16.60+29.9%+41.6%$1.50B$59.61M-7.14150Upcoming EarningsAMPHAmphastar Pharmaceuticals4.427 of 5 stars$31.02-2.3%$50.33+62.3%-40.3%$1.49B$644.40M10.341,761IMCRImmunocore1.4324 of 5 stars$29.60-0.5%$65.64+121.7%-56.8%$1.48B$249.43M-31.16320AAPGAscentage Pharma Group InternationalN/A$18.24+5.7%N/AN/A$1.44BN/A0.00600News CoverageGap UpKNSAKiniksa Pharmaceuticals3.1789 of 5 stars$19.74+0.5%$36.60+85.4%-1.2%$1.43B$270.26M-140.99220Upcoming EarningsDYNDyne Therapeutics3.0616 of 5 stars$13.91-1.0%$49.91+258.8%-38.5%$1.42BN/A-3.91100GPCRStructure Therapeutics2.4906 of 5 stars$24.39+0.1%$81.29+233.3%-46.1%$1.40BN/A-32.96136ARDXArdelyx4.3491 of 5 stars$5.79+2.3%$9.42+62.6%-33.1%$1.37B$124.46M-19.3090Earnings ReportAnalyst ForecastInsider TradeNews CoverageINDVIndivior2.6171 of 5 stars$9.83-2.5%$16.00+62.8%-46.0%$1.36B$1.09B-245.691,164Earnings ReportUpcoming EarningsNews CoverageNRIXNurix Therapeutics1.5649 of 5 stars$17.59+0.1%$31.81+80.9%+68.9%$1.33B$54.55M-6.09300 Related Companies and Tools Related Companies Arcutis Biotherapeutics Alternatives Amphastar Pharmaceuticals Alternatives Immunocore Alternatives Ascentage Pharma Group International Alternatives Kiniksa Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Structure Therapeutics Alternatives Ardelyx Alternatives Indivior Alternatives Nurix Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHAT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
